There is an urgent need to identify biomarkers to guide personalized therapy in castration-resistant prostate cancer (CRPC). We aimed to clinically qualify androgen receptor (AR) gene status measurement in plasma DNA using multiplex droplet digital PCR (ddPCR) in pre- and post-chemotherapy CRPC.
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study / Conteduca, V; Wetterskog, D; Sharabiani, M. T. A; Grande, Elisabetta; Fernandez Perez, M. P; Jayaram, A; Salvi, S; Castellano, D; Romanel, Alessandro; Lolli, C; Casadio, V; Gurioli, G; Amadori, D; Font, A; Vazquez Estevez, S; González Del Alba, A; Mellado, B; Fernandez Calvo, O; Méndez Vidal, M. J; Climent, M. A; Duran, I; Gallardo, E; Rodriguez, A; Santander, C; Sáez, M. I; Puente, J; Gasi Tandefelt, D; Wingate, A; Dearnaley, D; Demichelis, Francesca; De Giorgi, U; Gonzalez Billalabeitia, E; Attard, G.. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 2017:(2017). [10.1093/annonc/mdx155]
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study
Romanel, Alessandro;Demichelis, Francesca;
2017-01-01
Abstract
There is an urgent need to identify biomarkers to guide personalized therapy in castration-resistant prostate cancer (CRPC). We aimed to clinically qualify androgen receptor (AR) gene status measurement in plasma DNA using multiplex droplet digital PCR (ddPCR) in pre- and post-chemotherapy CRPC.| File | Dimensione | Formato | |
|---|---|---|---|
|
mdx155.pdf
accesso aperto
Tipologia:
Versione editoriale (Publisher’s layout)
Licenza:
Creative commons
Dimensione
328.16 kB
Formato
Adobe PDF
|
328.16 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione
